Real-life effect of a microcrystalline tyrosine adjuvanted mite immunotherapy in patients with allergic rhinitis
In this study, investigators evaluate the effectiveness and safety of immunotherapy with Acarovac Plus® in a 1-year prospective multicentered real-life study.
Allergic rhinitis is a highly prevalent allergic disease and one of the most frequent reasons for medical consultation. Sensitization to house dust mite airborne allergens is recognized as a causative factor for both allergic rhinitis and allergic asthma. Avoidance of house dust mites is not always feasible, and patients worldwide are suffering rhinitis symptoms such as runny nose, watery eyes, sneezing or nasal congestion that have a great impact on their daily life.
Traditional pharmacotherapy with antihistamines or corticosteroids provides symptomatic relief but does not offer long-term benefits, since the natural progression of the disease remains unaffected. Allergen-specific immunotherapy consists of administering the specific allergen to an allergic person in order to increase their immunological tolerance and to decrease the symptoms associated with subsequent exposure to the causative allergen. This therapy addresses the immune cause of the disease.
In this study, investigators led by Albert Roger (Hospital Germans Trias i Pujol; Badalona, Spain) evaluate the effectiveness and safety of immunotherapy with Acarovac Plus® in a 1-year prospective multicentered real-life study.